后发性白内障是现代白内障囊外摘除手术后导致视力下降的最常见并发症。在后发性白内障药物防治研究中 ,如何选择最佳给药途径以维持药物有效浓度并减少其毒副作用 ,是研究的难点。近年来 ,应用单克隆抗体特异性抑制晶状体上皮细胞增殖以及“自杀基因”的应用 ,为药物研究提供了安全、特异、高效的手段。本文就后发性白内障防治的药物缓释研究、免疫导向治疗、基因治疗等作一综述 Posterior cataract is the most common complication of vision loss after extracapsular cataract extraction in modern cataract surgery. In the study of the prevention and treatment of posterior capsular diseases, how to choose the best route of administration to maintain the effective concentration of the drug and reduce its toxic side effects is the research difficult. In recent years, the use of monoclonal antibodies to specifically inhibit the proliferation of lens epithelial cells and the application of “suicide gene” provide safe, specific and efficient means for drug research. This article reviews the drug-controlled release of delayed cataract, immune-directed therapy and gene therapy